Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00044694 on ClinicalTrials.gov · last registry update 2015-02-20

Finished May 2003, after enrolling 156 people. Primary outcome, as filed: Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 156
Started: 2002-08
Primary completion: 2003-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28

Conditions studied

Diabetes Mellitus, Non-Insulin-Dependent

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.